Discover an awarding winning abstract from EASL 2025 that has called for more person-centred hepatitis screening. Learn more.

An antisense drug in development at GSK has shown further activity against hepatitis B virus (HBV ... bepirovirsen as a monotherapy in the first half of next year, and is also exploring use ...

SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, ...

GSK has revealed updated results from its phase 2b trial of its antisense drug for hepatitis B virus (HBV ... 3 programme due to start in the first half of 2023. Hepatitis B affects almost ...

Net Loss: For the first quarter of 2025, the Company generated a net loss attributable to its shareholders of $19.6 million, ...

Both those infected by contaminated blood products and those affected by the scandal - such as partners, parents, children ...

Dengue fever poses a growing global threat, putting 4 billion people at risk with no targeted treatments available.

Story March 27 - Nkarta: The South San Francisco-based company is laying off 34% of its workforce—representing 53 employees—including half of ... for chronic hepatitis B viral infection ...

Vir Biotechnology, Inc. progresses HDV treatment with promising ECLIPSE program results. Click here to find out why VIR stock ...

Discover a recent study presented at EASL 2025 that explored the impact of opt-out testing for blood-borne viruses in ...

Find him on Twitter @GabeWhisnant. On Monday, President Donald Trump defended an artificial intelligence (AI)-generated image of himself dressed as the pope that was shared to his Truth Social ...